HK1151467A1 - Cyclodextrin-based polymers for delivering the therapeutic agents covalently bound thereto - Google Patents
Cyclodextrin-based polymers for delivering the therapeutic agents covalently bound theretoInfo
- Publication number
- HK1151467A1 HK1151467A1 HK11105534.9A HK11105534A HK1151467A1 HK 1151467 A1 HK1151467 A1 HK 1151467A1 HK 11105534 A HK11105534 A HK 11105534A HK 1151467 A1 HK1151467 A1 HK 1151467A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- cyclodextrin
- therapeutic
- methods
- therapeutic agents
- relates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B30/00—Preparation of starch, degraded or non-chemically modified starch, amylose, or amylopectin
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B31/00—Preparation of derivatives of starch
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
- C08G63/91—Polymers modified by chemical after-treatment
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
- C08G69/44—Polyester-amides
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G81/00—Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers
- C08G81/02—Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers at least one of the polymers being obtained by reactions involving only carbon-to-carbon unsaturated bonds
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H70/00—ICT specially adapted for the handling or processing of medical references
- G16H70/40—ICT specially adapted for the handling or processing of medical references relating to drugs, e.g. their side effects or intended usage
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
- C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
- C08F220/10—Esters
- C08F220/26—Esters containing oxygen in addition to the carboxy oxygen
- C08F220/28—Esters containing oxygen in addition to the carboxy oxygen containing no aromatic rings in the alcohol moiety
- C08F220/282—Esters containing oxygen in addition to the carboxy oxygen containing no aromatic rings in the alcohol moiety and containing two or more oxygen atoms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medical Informatics (AREA)
- Materials Engineering (AREA)
- Biochemistry (AREA)
- Nanotechnology (AREA)
- Primary Health Care (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Toxicology (AREA)
- Inorganic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Business, Economics & Management (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40885502P | 2002-09-06 | 2002-09-06 | |
US42283002P | 2002-10-31 | 2002-10-31 | |
US45199803P | 2003-03-04 | 2003-03-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1151467A1 true HK1151467A1 (en) | 2012-02-03 |
Family
ID=31982363
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK05104980.9A HK1072202A1 (en) | 2002-09-06 | 2005-06-15 | Cyclodextrin-based polymers for delivering the therapeutic agents covalently bound thereto |
HK11105534.9A HK1151467A1 (en) | 2002-09-06 | 2005-06-15 | Cyclodextrin-based polymers for delivering the therapeutic agents covalently bound thereto |
HK18113565.8A HK1254600A1 (zh) | 2002-09-06 | 2018-10-23 | 用於輸送與其共價結合喜樹鹼的基於環糊精的聚合物 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK05104980.9A HK1072202A1 (en) | 2002-09-06 | 2005-06-15 | Cyclodextrin-based polymers for delivering the therapeutic agents covalently bound thereto |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK18113565.8A HK1254600A1 (zh) | 2002-09-06 | 2018-10-23 | 用於輸送與其共價結合喜樹鹼的基於環糊精的聚合物 |
Country Status (17)
Country | Link |
---|---|
US (20) | US7270808B2 (he) |
EP (4) | EP2402036B1 (he) |
JP (4) | JP2006502301A (he) |
KR (6) | KR20140070676A (he) |
CN (2) | CN102516417B (he) |
AT (1) | ATE533513T1 (he) |
AU (2) | AU2003278764C1 (he) |
BR (2) | BR122012021252B8 (he) |
CA (1) | CA2497792C (he) |
CY (2) | CY1112362T1 (he) |
ES (3) | ES2417324T3 (he) |
HK (3) | HK1072202A1 (he) |
IL (2) | IL234716A0 (he) |
MX (2) | MX367615B (he) |
PT (2) | PT1534340E (he) |
TW (2) | TWI422379B (he) |
WO (1) | WO2004022099A2 (he) |
Families Citing this family (215)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8106098B2 (en) * | 1999-08-09 | 2012-01-31 | The General Hospital Corporation | Protein conjugates with a water-soluble biocompatible, biodegradable polymer |
US7141540B2 (en) * | 2001-11-30 | 2006-11-28 | Genta Salus Llc | Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof |
DE60323936D1 (de) * | 2002-01-14 | 2008-11-20 | Gen Hospital Corp | Bioabbaubare polyketale, verfahren zu ihrer herstellung sowie ihre verwendung |
CA2492803C (en) * | 2002-07-19 | 2013-11-05 | The General Hospital Corporation | Oxime conjugates and methods for their formation and use |
MX367615B (es) | 2002-09-06 | 2019-08-28 | Cerulean Pharma Inc | Polimeros a base de ciclodextrina para el suministro de agentes terapeuticos. |
EP1549269A4 (en) * | 2002-10-09 | 2010-10-06 | Cerulean Pharma Inc | CYCLODEXTRIN BASED MATERIALS, COMPOSITIONS AND ITS USE |
SG129240A1 (en) * | 2003-01-23 | 2007-02-26 | Agency Science Tech & Res | Biodegradable copolymer and nucleic acid delivery system |
JP4009721B2 (ja) * | 2003-05-23 | 2007-11-21 | 独立行政法人産業技術総合研究所 | イオン結合性ポリマー含有基板、該基板を含有する検出用センサー及び病原菌又は病原菌が生産する毒素の検出方法 |
US7790150B2 (en) * | 2003-09-05 | 2010-09-07 | The General Hospital Corporation | Dual phase drug release system |
US6960300B2 (en) * | 2003-09-08 | 2005-11-01 | Sami Labs Limited | Process for preparing water soluble diterpenes and their applications |
US8394365B2 (en) | 2003-09-17 | 2013-03-12 | Nektar Therapeutics | Multi-arm polymer prodrugs |
SI1675622T1 (sl) * | 2003-09-17 | 2017-09-29 | Nektar Therapeutics | Večkraka polimerna predzdravila |
PT1696920E (pt) | 2003-12-19 | 2015-01-14 | Plexxikon Inc | Compostos e métodos para o desenvolvimento de moduladores de ret |
EP1742962B1 (en) * | 2004-04-23 | 2016-11-23 | Expedeon Limited | Methods and kits for folding proteins in the presence of linear or branched sugar polymers |
WO2005120578A2 (en) * | 2004-06-07 | 2005-12-22 | California Institute Of Technology | Biodegradable drug-polymer delivery system |
US7498342B2 (en) * | 2004-06-17 | 2009-03-03 | Plexxikon, Inc. | Compounds modulating c-kit activity |
WO2006012527A1 (en) | 2004-07-23 | 2006-02-02 | Endocyte, Inc. | Bivalent linkers and conjugates thereof |
EP1807092B1 (en) | 2004-11-05 | 2016-09-07 | The Children's Hospital of Philadelphia | Biodegradable linkers for molecular therapies |
TW200640493A (en) * | 2005-02-16 | 2006-12-01 | Insert Therapeutics Inc | Cyclodextrin-based polymers for therapeutics delivery |
JP2008537551A (ja) | 2005-03-31 | 2008-09-18 | カランド ファーマシューティカルズ, インコーポレイテッド | リボヌクレオチドレダクターゼサブユニット2の阻害剤およびその使用 |
EP1885723A2 (en) * | 2005-05-17 | 2008-02-13 | Plexxikon, Inc. | Pyrrolo[2,3-b]pyridine derivatives as protein kinase inhibitors |
RS52010B (en) | 2005-06-22 | 2012-04-30 | Plexxikon Inc. | DERIVATI PIROLO [2, 3-B] PIRIDINA KAO INHIBITORI PROTEIN KINAZE |
US20070021380A1 (en) * | 2005-07-22 | 2007-01-25 | Leonard Wiebe | Novel drug delivery compositions |
GT200600381A (es) | 2005-08-25 | 2007-03-28 | Compuestos organicos | |
EP1931658A2 (en) * | 2005-09-07 | 2008-06-18 | Plexxikon, Inc. | 1 , 4 and 1 , 5-disubstituted indole derivatives for use as ppar active compounds |
BRPI0615948A2 (pt) * | 2005-09-07 | 2011-05-31 | Plexxikon Inc | composto ativo de ppar, sua composição, seu kit e seu uso |
AU2006287513A1 (en) * | 2005-09-07 | 2007-03-15 | Plexxikon, Inc. | 1, 3-disubstituted indole derivatives for use as PPAR modulators |
WO2007072481A2 (en) * | 2005-12-19 | 2007-06-28 | Capsutech Ltd. | Cyclodextrin-containing polymers and uses thereof |
US7462627B2 (en) * | 2006-02-09 | 2008-12-09 | Enzon Pharmaceuticals, Inc. | Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers |
US7671067B2 (en) * | 2006-02-09 | 2010-03-02 | Enzon Pharmaceuticals, Inc. | Treatment of non-hodgkin's lymphomas with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamtothecin |
CN103420877B (zh) | 2006-03-29 | 2015-08-12 | 诺瓦提斯公司 | 基于异羟肟酸酯的选择性mmp抑制剂 |
US20080027212A1 (en) | 2006-06-28 | 2008-01-31 | Skinner Keith K | Methods and compositions for improved uptake of biological molecules |
KR101149274B1 (ko) | 2006-07-20 | 2012-05-29 | 노파르티스 아게 | Cετρ 억제제로서의 아미노-피페리딘 유도체 |
WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
MX2009005780A (es) | 2006-11-30 | 2009-06-10 | Nektar Therapeutics Al Corp | Metodo para preparar un conjugado de polimeros. |
TWI528976B (zh) * | 2006-12-13 | 2016-04-11 | 斯茹林製藥公司 | 用於醫物傳遞之以環糊精為基之聚合物 |
PE20121126A1 (es) * | 2006-12-21 | 2012-08-24 | Plexxikon Inc | Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa |
WO2008079909A1 (en) * | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Pyrrolo [2,3-b] pyridines as kinase modulators |
RU2009122670A (ru) | 2006-12-21 | 2011-01-27 | Плекссикон, Инк. (Us) | Соединения и способы для модуляции киназ и показания к их применению |
JP2010516625A (ja) * | 2007-01-24 | 2010-05-20 | インサート セラピューティクス, インコーポレイテッド | 制御された薬物送達のためのテザー基を有するポリマー−薬物コンジュゲート |
CA2677798A1 (en) * | 2007-02-09 | 2008-08-14 | Enzon Pharmaceuticals, Inc. | Treatment of resistant or refractory cancers with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin |
PE20090159A1 (es) * | 2007-03-08 | 2009-02-21 | Plexxikon Inc | COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs |
CA2680535C (en) | 2007-03-14 | 2016-09-20 | Endocyte, Inc. | Binding ligand linked drug delivery conjugates of tubulysins |
US9877965B2 (en) | 2007-06-25 | 2018-01-30 | Endocyte, Inc. | Vitamin receptor drug delivery conjugates for treating inflammation |
WO2009002993A1 (en) | 2007-06-25 | 2008-12-31 | Endocyte, Inc. | Conjugates containing hydrophilic spacer linkers |
US20100190777A1 (en) | 2007-07-17 | 2010-07-29 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
EP2207570A2 (en) * | 2007-09-14 | 2010-07-21 | Nitto Denko Corporation | Drug carriers |
JP5597396B2 (ja) * | 2007-09-28 | 2014-10-01 | ナノデックス株式会社 | 葉酸修飾されたシクロデキストリン化合物、その製造方法、標的指向性薬物送達システム用の薬物送達剤、医薬組成物及び造影剤 |
EP2200649A4 (en) | 2007-10-19 | 2012-09-26 | Univ California | COMPOSITIONS AND METHODS FOR TREATING CNS INFUSION, PSYCHOSIS, DELIRE, PTSD OR PTSS |
PE20090982A1 (es) | 2007-11-05 | 2009-08-13 | Novartis Ag | Derivados de piperidina como inhibidores de la proteina de transferencia de colesteril-ester (cetp) |
EP2229356B1 (en) | 2007-12-03 | 2011-10-12 | Novartis AG | 1,2-disubstituted-4-benzylamino-pyrrolidine derivatives as cetp inhibitors useful for the treatment of diseases such as hyperli pidemia or arteriosclerosis |
EA020114B1 (ru) | 2008-03-24 | 2014-08-29 | Новартис Аг | Производные арилсульфонамида в качестве ингибиторов матриксной металлопротеазы |
EP2269072B1 (en) | 2008-03-31 | 2017-08-23 | Boston Medical Center Corporation | Predictive marker for topoisomerase i inhibitors |
WO2009123764A2 (en) | 2008-04-04 | 2009-10-08 | Calando Pharmaceuticals, Inc. | Compositions and use of epas1 inhibitors |
PE20091846A1 (es) * | 2008-05-19 | 2009-12-16 | Plexxikon Inc | DERIVADOS DE PIRROLO[2,3-d]-PIRIMIDINA COMO MODULADORES DE CINASAS |
US8158636B2 (en) * | 2008-05-19 | 2012-04-17 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
CN104530052A (zh) * | 2008-06-10 | 2015-04-22 | 普莱希科公司 | 用于激酶调节的5h-吡咯[2,3-b]吡嗪衍生物和其适应症 |
WO2009152087A1 (en) * | 2008-06-10 | 2009-12-17 | Plexxikon, Inc. | Bicyclic heteroaryl compounds and methods for kinase modulation, and indications therefor |
EP2331140B1 (en) | 2008-08-11 | 2018-07-04 | Nektar Therapeutics | Multi-arm polymeric alkanoate conjugates |
KR101661746B1 (ko) | 2008-08-13 | 2016-09-30 | 캘리포니아 인스티튜트 오브 테크놀로지 | 캐리어 나노입자, 그리고 관련된 조성물, 방법 및 시스템 |
WO2010025337A1 (en) * | 2008-08-29 | 2010-03-04 | Enzon Pharmaceuticals, Inc. | Method of treating ras associated cancer |
US20100068153A1 (en) * | 2008-09-16 | 2010-03-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Ex vivo activatable final dosage form |
US20100068283A1 (en) * | 2008-09-16 | 2010-03-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Ex VIVO modifiable particle or polymeric material medicament carrier |
US20100068275A1 (en) * | 2008-09-16 | 2010-03-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Personalizable dosage form |
SI2349346T1 (sl) | 2008-09-23 | 2019-12-31 | Nektar Therapeutics | Postopek metronomskega doziranja s kamptotekinskim predzdravilom (npr. PEG-irinotekan) |
JP2012506380A (ja) * | 2008-10-21 | 2012-03-15 | エンゾン ファーマシューティカルズ,インコーポレーテッド | 7−エチル−10−ヒドロキシカンプトテシンのマルチアーム型ポリマーコンジュゲートによる神経芽腫の治療 |
EP2359852A4 (en) * | 2008-11-17 | 2015-05-20 | Nat Cancer Ct | NEW CANCERED THERAPY WITH A SUBSTANCE COMPLEX SPECIFICALLY BINDING TO A TUMOR STREAM FACTOR AND ANTITUMIR COMPOUND |
PA8853201A1 (es) * | 2008-12-10 | 2010-07-27 | Mersana Therapeutics Inc | Formulaciones farmaceuticas de conjugados de camtotecina-polimero biocompatibles biodegradables |
US8309530B2 (en) * | 2009-02-04 | 2012-11-13 | Washington State University | Compositions and methods for modulating ghrelin-mediated conditions |
CN102414116B (zh) | 2009-02-26 | 2015-01-21 | 加利福尼亚大学董事会 | 用于制备尺寸可控的纳米颗粒的超分子方法 |
CN102421776A (zh) | 2009-03-11 | 2012-04-18 | 普莱希科公司 | 抑制Raf激酶的吡咯并[2,3-b]吡啶衍生物 |
TW201036972A (en) * | 2009-03-11 | 2010-10-16 | Plexxikon Inc | Compounds and uses thereof |
EP2414356B1 (en) | 2009-04-03 | 2015-09-02 | F.Hoffmann-La Roche Ag | Propane-i-sulfonic acid {3-[5-(4-chloro-phenyl)-1h-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide compositions and uses thereof |
TW201041888A (en) * | 2009-05-06 | 2010-12-01 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
JP5747432B2 (ja) * | 2009-05-28 | 2015-07-15 | 国立大学法人秋田大学 | 2置換修飾シクロデキストリンおよびこれを用いた核酸検出方法 |
WO2010138802A2 (en) * | 2009-05-28 | 2010-12-02 | Cornell University | Compositions and their use for removing cholesterol |
US8329724B2 (en) | 2009-08-03 | 2012-12-11 | Hoffmann-La Roche Inc. | Process for the manufacture of pharmaceutically active compounds |
US20110152512A1 (en) * | 2009-09-09 | 2011-06-23 | John Ryan | Cyclodextrin-based polymers for therapeutics delivery |
US20120114658A1 (en) * | 2009-09-15 | 2012-05-10 | John Ryan | Treatment of cancer |
EA201200486A1 (ru) * | 2009-09-15 | 2012-08-30 | Серулин Фарма Инк. | Лечение онкологических заболеваний |
US8381774B2 (en) * | 2009-09-20 | 2013-02-26 | Medtronic Vascular, Inc. | Methods for loading a drug eluting medical device |
CN106220623A (zh) | 2009-11-06 | 2016-12-14 | 普莱希科公司 | 用于激酶调节的化合物和方法及其适应症 |
MX2012005827A (es) * | 2009-11-18 | 2012-06-19 | Plexxikon Inc | Compuestos y metodos para la modulacion de cinasas, e indicaciones para ello. |
CN102781237A (zh) * | 2009-11-23 | 2012-11-14 | 天蓝制药公司 | 用于传递治疗剂的基于环糊精的聚合物 |
WO2011079133A2 (en) * | 2009-12-23 | 2011-06-30 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
US20120004195A1 (en) * | 2010-01-19 | 2012-01-05 | Alexandra Glucksmann | Cyclodextrin-based polymers for therapeutic delivery |
US20110178287A1 (en) * | 2010-01-19 | 2011-07-21 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutic delivery |
JP2011190341A (ja) * | 2010-03-15 | 2011-09-29 | Nano Dex Kk | シクロデキストリン化合物 |
WO2011119995A2 (en) | 2010-03-26 | 2011-09-29 | Cerulean Pharma Inc. | Formulations and methods of use |
WO2011119262A1 (en) | 2010-03-26 | 2011-09-29 | Cerulean Pharma Inc. | Methods and systems for generating nanoparticles |
JP2013528665A (ja) | 2010-03-26 | 2013-07-11 | メルサナ セラピューティックス, インコーポレイテッド | ポリヌクレオチドの送達のための修飾ポリマー、その製造方法、およびその使用方法 |
US20120064107A1 (en) * | 2010-05-18 | 2012-03-15 | Cerulean Pharma Inc. | Compositions and methods for treatment of autoimmune and other disease |
CA2799202C (en) | 2010-05-18 | 2016-07-05 | Cerulean Pharma Inc. | Compositions and methods for treatment of autoimmune and other diseases |
US8822663B2 (en) | 2010-08-06 | 2014-09-02 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
WO2012044832A1 (en) * | 2010-09-30 | 2012-04-05 | Fetzer Oliver S | Methods of treating a subject and related particles, polymers and compositions |
HUE058896T2 (hu) | 2010-10-01 | 2022-09-28 | Modernatx Inc | N1-metil-pszeudo-uracilt tartalmazó ribonukleinsavak és azok felhasználásai |
US20130331443A1 (en) | 2010-12-22 | 2013-12-12 | Nektar Therapeutics | Multi-arm polymeric prodrug conjugates of taxane-based compounds |
WO2012088445A1 (en) | 2010-12-22 | 2012-06-28 | Nektar Therapeutics | Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds |
WO2012092339A2 (en) * | 2010-12-28 | 2012-07-05 | The Children's Hospital Of Philadelphia | The design of hydrolytically releasable prodrugs for sustained release nanoparticle formulations |
WO2012103182A1 (en) | 2011-01-28 | 2012-08-02 | Cerulean Pharma Inc. | Method for fabricating nanoparticles |
EA028821B9 (ru) | 2011-02-07 | 2018-10-31 | Плексксикон, Инк. | Соединения и способы для модуляции киназ, а также показания к их применению |
AR085279A1 (es) | 2011-02-21 | 2013-09-18 | Plexxikon Inc | Formas solidas de {3-[5-(4-cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico |
US8710200B2 (en) | 2011-03-31 | 2014-04-29 | Moderna Therapeutics, Inc. | Engineered nucleic acids encoding a modified erythropoietin and their expression |
US20120302505A1 (en) * | 2011-04-21 | 2012-11-29 | Fetzer Oliver S | Cyclodextrin-based polymers for therapeutic delivery |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
RS62993B1 (sr) | 2011-10-03 | 2022-03-31 | Modernatx Inc | Modifikovani nukleozidi, nukleotidi, i nukleinske kiseline, i njihove upotrebe |
CN104114572A (zh) | 2011-12-16 | 2014-10-22 | 现代治疗公司 | 经修饰的核苷、核苷酸和核酸组合物 |
JP2015505559A (ja) * | 2012-01-31 | 2015-02-23 | セルリアン・ファーマ・インコーポレイテッド | 治療剤送達のためのシクロデキストリン系ポリマー |
WO2013126797A1 (en) | 2012-02-24 | 2013-08-29 | Purdue Research Foundation | Cholecystokinin b receptor targeting for imaging and therapy |
EP2826492A4 (en) * | 2012-03-13 | 2015-10-21 | Postech Acad Ind Found | CONJUGATE DRUG DELIVERY DESIGNED FOR PROLONGED RELEASE AND USE THEREOF |
US9358235B2 (en) | 2012-03-19 | 2016-06-07 | Plexxikon Inc. | Kinase modulation, and indications therefor |
US20140080175A1 (en) | 2012-03-29 | 2014-03-20 | Endocyte, Inc. | Processes for preparing tubulysin derivatives and conjugates thereof |
US9303079B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
DE18200782T1 (de) | 2012-04-02 | 2021-10-21 | Modernatx, Inc. | Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9598503B2 (en) * | 2012-04-18 | 2017-03-21 | Cerulean Pharma Inc. | Methods and systems for polymer precipitation and generation of particles |
KR102309973B1 (ko) | 2012-05-16 | 2021-10-06 | 테크필즈 파마 코., 엘티디. | 폐 병태의 치료를 위한 고침투 전구약물 조성물 및 그의 약제학적 조성물 |
US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
US9827321B2 (en) | 2012-08-14 | 2017-11-28 | The Trustees Of The University Of Pennsylvania | Stabilizing shear-thinning hydrogels |
WO2014039714A2 (en) | 2012-09-06 | 2014-03-13 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US20140094432A1 (en) | 2012-10-02 | 2014-04-03 | Cerulean Pharma Inc. | Methods and systems for polymer precipitation and generation of particles |
WO2014062697A2 (en) | 2012-10-16 | 2014-04-24 | Endocyte, Inc. | Drug delivery conjugates containing unnatural amino acids and methods for using |
WO2014070233A1 (en) | 2012-10-29 | 2014-05-08 | Boston Medical Center Corporation | Brca1 mutations as predictive markers for topoisomerase i inhibitors |
EP4074834A1 (en) | 2012-11-26 | 2022-10-19 | ModernaTX, Inc. | Terminally modified rna |
US9919059B2 (en) | 2012-12-10 | 2018-03-20 | Massachusetts Institute Of Technology | Multistage nanoparticle drug delivery system for the treatment of solid tumors |
CN103044349B (zh) * | 2012-12-13 | 2014-05-21 | 浙江大学 | 一种微波辅助纳米铁酸盐制备乙二胺四乙酸酐的方法 |
BR112015014752B1 (pt) | 2012-12-21 | 2022-07-05 | Plexxikon, Inc | Compostos e seus uso para modulação de cinase |
CN105142620B (zh) * | 2013-02-25 | 2018-09-28 | 罗切斯特大学 | 用于受控释放抗生物膜剂的纳米颗粒 |
US9132097B2 (en) | 2013-03-01 | 2015-09-15 | California Institute Of Technology | Nanoparticles stabilized with nitrophenylboronic acid compositions |
US9468681B2 (en) | 2013-03-01 | 2016-10-18 | California Institute Of Technology | Targeted nanoparticles |
CN105209916A (zh) | 2013-03-14 | 2015-12-30 | 华盛顿大学商业中心 | 聚合物点组合物和相关方法 |
EP2971010B1 (en) | 2013-03-14 | 2020-06-10 | ModernaTX, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
RU2680100C9 (ru) | 2013-03-15 | 2019-04-18 | Плексксикон Инк. | Гетероциклические соединения и их применения |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
US9873700B2 (en) | 2013-05-30 | 2018-01-23 | Plexxikon Inc. | Compounds for kinase modulation, and indications therefor |
EP3030902B1 (en) | 2013-08-07 | 2019-09-25 | Friedrich Miescher Institute for Biomedical Research | New screening method for the treatment friedreich's ataxia |
AU2014315287A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
EP3041938A1 (en) | 2013-09-03 | 2016-07-13 | Moderna Therapeutics, Inc. | Circular polynucleotides |
EP3052106A4 (en) | 2013-09-30 | 2017-07-19 | ModernaTX, Inc. | Polynucleotides encoding immune modulating polypeptides |
MX2016004249A (es) | 2013-10-03 | 2016-11-08 | Moderna Therapeutics Inc | Polinulcleotidos que codifican el receptor de lipoproteina de baja densidad. |
CN109806027A (zh) | 2013-11-01 | 2019-05-28 | 雷恩斯根公司 | 双部件调节性人工晶状体设备 |
US9771369B2 (en) | 2014-03-04 | 2017-09-26 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US10653709B2 (en) * | 2014-05-19 | 2020-05-19 | North Carolina State University | Methods of folding a graft copolymer with dual anticancer drugs and related applications |
KR102062025B1 (ko) * | 2014-06-30 | 2020-01-03 | 타베다 세라퓨틱스, 인코포레이티드 | 표적화된 콘주게이트 및 입자 및 그것의 제형 |
WO2016011226A1 (en) | 2014-07-16 | 2016-01-21 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
US20170210788A1 (en) | 2014-07-23 | 2017-07-27 | Modernatx, Inc. | Modified polynucleotides for the production of intrabodies |
US10004596B2 (en) | 2014-07-31 | 2018-06-26 | Lensgen, Inc. | Accommodating intraocular lens device |
ES2774177T3 (es) | 2014-09-15 | 2020-07-17 | Plexxikon Inc | Compuestos heterocíclicos y usos de estos |
CN104274837B (zh) * | 2014-09-18 | 2017-01-11 | 福格森(武汉)生物科技股份有限公司 | 一种尼洛替尼口服制剂 |
CN104311820B (zh) * | 2014-09-24 | 2017-06-20 | 北京化工大学 | 一种基于多糖接枝聚天冬氨酸苄酯构建可降解药物载体的方法 |
US10160755B2 (en) | 2015-04-08 | 2018-12-25 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
TWI547308B (zh) * | 2015-06-10 | 2016-09-01 | 聚和國際股份有限公司 | 聚電解質膠囊的製備方法及所製得的聚電解質膠囊 |
CN107922609B (zh) | 2015-07-01 | 2020-04-24 | 加州理工学院 | 基于阳离子粘酸聚合物的递送系统 |
WO2017006279A1 (en) * | 2015-07-08 | 2017-01-12 | Aten Porus Lifesciences | Cyclodextrin-polymer complexes and compostions and methods of making and using the same |
ES2862191T3 (es) | 2015-07-22 | 2021-10-07 | Nitto Denko Corp | Composiciones y métodos para formas de liófilos de nanopartículas |
WO2017019804A2 (en) | 2015-07-28 | 2017-02-02 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US11458205B2 (en) | 2015-08-04 | 2022-10-04 | Duke University | Genetically encoded intrinsically disordered stealth polymers for delivery and methods of using same |
NZ741112A (en) | 2015-09-21 | 2021-07-30 | Plexxikon Inc | Heterocyclic compounds and uses thereof |
AU2016343817B2 (en) | 2015-10-28 | 2021-05-27 | Tva (Abc), Llc | SSTR-targeted conjugates and particles and formulations thereof |
EP3383320A4 (en) | 2015-12-01 | 2019-08-21 | Lensgen, Inc | AKKOMODATIVE INTRAOCULAR LENS DEVICE |
US20180271998A1 (en) | 2015-12-04 | 2018-09-27 | Merrimack Pharmaceuticals, Inc. | Disulfide-stabilized fabs |
WO2017106630A1 (en) | 2015-12-18 | 2017-06-22 | The General Hospital Corporation | Polyacetal polymers, conjugates, particles and uses thereof |
US11752213B2 (en) | 2015-12-21 | 2023-09-12 | Duke University | Surfaces having reduced non-specific binding and antigenicity |
RU2018128032A (ru) * | 2016-01-21 | 2020-02-25 | Атен Порус Лайфсайенсес | Полимеры на основе циклодекстрина, способы, композиции и применение |
WO2017176796A1 (en) | 2016-04-04 | 2017-10-12 | University Of Virginia Patent Foundation | Compositions and methods for preventing and treating disease |
US11467156B2 (en) | 2016-06-01 | 2022-10-11 | Duke University | Nonfouling biosensors |
CA3029813A1 (en) | 2016-06-13 | 2017-12-21 | Torque Therapeutics, Inc. | Methods and compositions for promoting immune cell function |
RU2019110848A (ru) | 2016-09-14 | 2020-10-15 | Дьюк Юниверсити | Наночастицы на основе триблочных полипептидов для доставки гидрофильных лекарственных средств |
TW201815766A (zh) | 2016-09-22 | 2018-05-01 | 美商普雷辛肯公司 | 用於ido及tdo調節之化合物及方法以及其適應症 |
KR20190064600A (ko) | 2016-09-23 | 2019-06-10 | 듀크 유니버시티 | Lcst 거동을 갖는 비구조화된 비-반복적 폴리펩티드 |
KR20190074310A (ko) | 2016-11-08 | 2019-06-27 | 리제너론 파마슈티칼스 인코포레이티드 | 스테로이드 및 이의 단백질-접합체 |
WO2018106738A1 (en) | 2016-12-05 | 2018-06-14 | Massachusetts Institute Of Technology | Brush-arm star polymers, conjugates and particles, and uses thereof |
US10703757B2 (en) | 2016-12-23 | 2020-07-07 | Plexxikon Inc. | Compounds and methods for CDK8 modulation and indications therefor |
WO2018127819A1 (en) | 2017-01-03 | 2018-07-12 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing alginates as biodegradable antibacterial scaffolds and methods pertaining thereto |
WO2018132732A1 (en) | 2017-01-12 | 2018-07-19 | Duke University | Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly |
EP3600338A4 (en) | 2017-03-28 | 2020-10-28 | The University of North Carolina at Chapel Hill | NITRIC OXIDE RELEASING POLYAMINOGLYCOSIDES AS BIODEGRADABLE ANTIBACTERIAL SCAFFOLDS AND RELATED PROCESSES |
WO2018213320A1 (en) | 2017-05-15 | 2018-11-22 | Duke University | Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents |
AU2018270784B2 (en) | 2017-05-18 | 2024-05-16 | Regeneron Pharmaceuticals, Inc. | Cyclodextrin protein drug conjugates |
WO2018226846A1 (en) | 2017-06-07 | 2018-12-13 | Plexxikon Inc. | Compounds and methods for kinase modulation |
EP3645530A2 (en) | 2017-06-30 | 2020-05-06 | Massachusetts Institute of Technology | Branched multi-functional macromonomers and related polymers and uses thereof |
WO2019006374A1 (en) | 2017-06-30 | 2019-01-03 | Duke University | ORDER AND DISORDER AS A DESIGN PRINCIPLE FOR STIMULI-SENSITIVE BIOPOLYMER NETWORKS |
CN112739345A (zh) | 2017-11-06 | 2021-04-30 | 斯奈普生物公司 | Pim激酶抑制剂组合物,方法和其用途 |
WO2019173539A1 (en) | 2018-03-06 | 2019-09-12 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing cyclodextrins as biodegradable antibacterial scaffolds and methods pertaining thereto |
AU2019239952A1 (en) | 2018-03-20 | 2020-10-08 | Plexxikon Inc. | Compounds and methods for IDO and TDO modulation, and indications therefor |
EP3788343B1 (en) * | 2018-04-30 | 2024-03-27 | Duke University | Stimuli-responsive peg-like polymer-based drug delivery platform |
CA3098453A1 (en) | 2018-05-09 | 2019-11-14 | Regeneron Pharmaceuticals, Inc. | Anti-msr1 antibodies and methods of use thereof |
WO2019241327A1 (en) | 2018-06-13 | 2019-12-19 | California Institute Of Technology | Nanoparticles for crossing the blood brain barrier and methods of treatment using the same |
EP3829622A4 (en) | 2018-08-02 | 2022-05-11 | Duke University | DUAL AGONIST FUSION PROTEINS |
EP3837266A1 (en) | 2018-08-17 | 2021-06-23 | Massachusetts Institute of Technology | Degradable polymers of a cyclic silyl ether and uses thereof |
JP2022516461A (ja) * | 2018-12-28 | 2022-02-28 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | 一酸化窒素放出抗菌性ポリマーおよびそれから製造された足場、ならびにそれに関する方法 |
WO2020160382A1 (en) * | 2019-01-31 | 2020-08-06 | Northwestern University | Supramolecular photoprotection of a photosensitizer |
US11446287B2 (en) | 2019-04-09 | 2022-09-20 | Opna Immuno-Oncology Sa | Compounds and methods for EP300 or CBP modulation and indications therefor |
CN114555610A (zh) | 2019-05-20 | 2022-05-27 | 麻省理工学院 | 硼酸酯前药及其用途 |
US11512314B2 (en) | 2019-07-12 | 2022-11-29 | Duke University | Amphiphilic polynucleotides |
KR20210071296A (ko) * | 2019-12-06 | 2021-06-16 | (주) 에이치엔에이파마켐 | 공유결합성 유기 골격체 및 폴리머를 이용한 경피전달용 복합체 |
US20210198239A1 (en) | 2019-12-06 | 2021-07-01 | Plexxikon Inc. | Compounds and methods for cd73 modulation and indications therefor |
WO2021141662A1 (en) | 2020-01-10 | 2021-07-15 | Massachusetts Institute Of Technology | Proteolysis targeting chimeric molecules (protacs) with functional handles and uses thereof |
CN111443068B (zh) * | 2020-03-06 | 2023-06-27 | 天津大学 | 具有多重刺激响应特性的纯有机室温磷光材料及筛选方法和应用 |
US20210315869A1 (en) | 2020-04-02 | 2021-10-14 | Plexxikon Inc. | Compounds and methods for csk modulation and indications therefor |
WO2021216898A1 (en) | 2020-04-23 | 2021-10-28 | Plexxikon Inc. | Compounds and methods for cd73 modulation and indications therefor |
WO2021257626A1 (en) * | 2020-06-15 | 2021-12-23 | Nanosynthons Llc | Excipients providing stabilization and enhanced water solubilization and their uses |
US20230285576A1 (en) | 2020-08-05 | 2023-09-14 | Ellipses Pharma Ltd | Treatment of cancer using a cyclodextrin-containing polymer-topoisomerase inhibitor conjugate and a parp inhibitor |
US20230081426A1 (en) | 2020-09-18 | 2023-03-16 | Plexxikon Inc. | Compounds and methods for kras modulation and indications therefor |
CN112755197B (zh) * | 2020-10-09 | 2023-01-13 | 黑龙江大学 | 一种环糊精药物包合物及其制备方法和应用 |
WO2022159319A2 (en) * | 2021-01-19 | 2022-07-28 | Mountain Valley Md Inc | A porous aluminum nanoparticulate structure |
EP4284919A1 (en) | 2021-01-29 | 2023-12-06 | Iovance Biotherapeutics, Inc. | Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy |
CN115160454A (zh) * | 2021-04-01 | 2022-10-11 | 四川大学 | 一种基于聚-β-环糊精与金刚烷主客体作用的超分子多醛化合物及其制备方法 |
CN113274541A (zh) * | 2021-05-10 | 2021-08-20 | 四川大学 | 一种抗菌型胶原基医用材料及其制备方法 |
KR20230050084A (ko) * | 2021-10-07 | 2023-04-14 | 주식회사 셀진 | Plga 및 약물을 함유하는 베타-사이클로덱스트린을 포함하는 약물 전달체 |
WO2023113479A1 (en) * | 2021-12-15 | 2023-06-22 | Sillajen, Inc. | Pharmaceutical compositions comprising modified beta-cyclodextrins |
WO2023147488A1 (en) | 2022-01-28 | 2023-08-03 | Iovance Biotherapeutics, Inc. | Cytokine associated tumor infiltrating lymphocytes compositions and methods |
CN114470237B (zh) * | 2022-03-21 | 2023-12-19 | 中国科学院长春应用化学研究所 | 一种类病毒结构基因载体、药物递送系统、其制备方法及其应用 |
CN115006549B (zh) * | 2022-06-16 | 2024-07-05 | 湖南科技大学 | 一种粒径可控及可控降解的酸敏型交联环糊精纳米水凝胶药物递送系统的制备方法 |
CN115340615B (zh) * | 2022-08-12 | 2023-05-02 | 同济大学 | 一种基于环糊精-氨基酸的荧光分子及其合成方法与应用 |
Family Cites Families (246)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2131201A (en) | 1928-08-04 | 1938-09-27 | Gen Motors Corp | Composite clutch |
US2129408A (en) | 1936-07-02 | 1938-09-06 | Arthur C Davidson | Truck stabilizer |
US2129401A (en) | 1937-09-09 | 1938-09-06 | Botinger Fred | Flexible utility ladder |
US2131208A (en) | 1938-02-26 | 1938-09-27 | Union Switch & Signal Co | Remote indication apparatus |
US3472835A (en) | 1964-02-12 | 1969-10-14 | American Mach & Foundry | Schardinger dextrins |
US3454530A (en) | 1966-03-07 | 1969-07-08 | Leslie C Case | Novel polyols which are reaction products of a monoepoxide and a cyclic monoanhydride |
US3426011A (en) | 1967-02-13 | 1969-02-04 | Corn Products Co | Cyclodextrins with anionic properties |
US3453257A (en) | 1967-02-13 | 1969-07-01 | Corn Products Co | Cyclodextrin with cationic properties |
US3654261A (en) | 1968-06-27 | 1972-04-04 | Cpc International Inc | Quaternary ammonium alkoxide alkoxy polyol compounds |
USRE32268E (en) | 1973-03-01 | 1986-10-21 | Strategic Medical Research Corp. | Therapeutic composition and method of therapeutically treating warm blooded animals therewith |
GB1390479A (en) | 1973-09-05 | 1975-04-16 | I Orch Sinteza Akademii Nauk L | Pharmaceutical composition for treatment of parkinsonism |
DE2843963A1 (de) | 1978-10-09 | 1980-04-24 | Merck Patent Gmbh | Im koerper resorbierbare geformte masse auf basis von kollagen und ihre verwendung in der medizin |
DE2842862A1 (de) | 1978-10-02 | 1980-04-10 | Boehringer Mannheim Gmbh | Verfahren zur bestimmung von ionen, polaren und/oder lipophilen substanzen in fluessigkeiten |
CA1190855A (en) | 1980-09-03 | 1985-07-23 | Rolf W. Pfirrmann | Treatment of osteitis |
JPS58113198A (ja) * | 1981-12-26 | 1983-07-05 | Hidetoshi Tsuchida | シクロデキストリンが結合したポルフイリン化合物 |
US4570629A (en) | 1982-03-17 | 1986-02-18 | University Of Illinois Foundation | Hydrophilic biopolymeric copolyelectrolytes, and biodegradable wound dressing comprising same |
JPS58167613A (ja) | 1982-03-26 | 1983-10-03 | Mitsubishi Petrochem Co Ltd | 水溶性シクロデキストリン含有重合体の製造法 |
EP0092918B1 (en) | 1982-04-22 | 1988-10-19 | Imperial Chemical Industries Plc | Continuous release formulations |
CA1208558A (en) | 1982-10-07 | 1986-07-29 | Kazuo Kigasawa | Soft buccal |
US4438253A (en) | 1982-11-12 | 1984-03-20 | American Cyanamid Company | Poly(glycolic acid)/poly(alkylene glycol) block copolymers and method of manufacturing the same |
HU191101B (en) * | 1983-02-14 | 1987-01-28 | Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu | Process for preparing water-soluble cyclodextrin polymers substituted with ionic groups |
ATE26584T1 (de) | 1983-07-01 | 1987-05-15 | Battelle Memorial Institute | In-vivo abbaubares polypeptid und dessen anwendung zur verzoegerten freigabe von medikamenten. |
US4525495A (en) | 1983-07-22 | 1985-06-25 | The Dow Chemical Company | Mineral filled composites |
JPS60100516A (ja) | 1983-11-04 | 1985-06-04 | Takeda Chem Ind Ltd | 徐放型マイクロカプセルの製造法 |
US4818542A (en) | 1983-11-14 | 1989-04-04 | The University Of Kentucky Research Foundation | Porous microspheres for drug delivery and methods for making same |
US4727064A (en) | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
GB8416234D0 (en) | 1984-06-26 | 1984-08-01 | Ici Plc | Biodegradable amphipathic copolymers |
US4625014A (en) | 1984-07-10 | 1986-11-25 | Dana-Farber Cancer Institute, Inc. | Cell-delivery agent |
CH663951A5 (fr) | 1984-10-10 | 1988-01-29 | Nestle Sa | Procede d'enrichissement selectif en acides gras polyinsatures d'un melange contenant des acides gras fractions enrichies obtenues et compositions les contenant. |
US4582865A (en) | 1984-12-06 | 1986-04-15 | Biomatrix, Inc. | Cross-linked gels of hyaluronic acid and products containing such gels |
US4638045A (en) | 1985-02-19 | 1987-01-20 | Massachusetts Institute Of Technology | Non-peptide polyamino acid bioerodible polymers |
JPH0651725B2 (ja) | 1985-02-28 | 1994-07-06 | メルシャン株式会社 | 部分メチル化シクロデキストリン及びその製造方法 |
GB8506792D0 (en) | 1985-03-15 | 1985-04-17 | Janssen Pharmaceutica Nv | Derivatives of y-cyclodextrin |
US4841081A (en) | 1985-10-16 | 1989-06-20 | Osaka Soda Co., Ltd. | Method of optically resolving a racemate or a diastereomeric mixture of glycidyl compound |
FR2601675B1 (fr) | 1986-07-17 | 1988-09-23 | Rhone Poulenc Sante | Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent |
EP0258780B1 (en) | 1986-09-05 | 1993-06-23 | American Cyanamid Company | Polyesters containing alkylene oxide blocks as drug delivery systems |
GB2197720A (en) | 1986-11-20 | 1988-05-25 | Nat Res Dev | Immobilisation of polynucleotides |
US5166320A (en) | 1987-04-22 | 1992-11-24 | University Of Connecticut | Carrier system and method for the introduction of genes into mammalian cells |
JP2993967B2 (ja) | 1987-06-17 | 1999-12-27 | インスティテュート・フォー・チャイルド・ヘルス・リサーチ | ダニアレルゲンのクローニング |
US4877778A (en) | 1987-07-01 | 1989-10-31 | The Children's Medical Center Corporation | Method of enhancing lipophile transport using cyclodextrin derivatives |
US4774329A (en) | 1987-08-04 | 1988-09-27 | American Maize-Products Company | Controlled release agent for cetylpyridinium chloride |
US4941996A (en) | 1987-10-19 | 1990-07-17 | Minnesota Mining And Manufacturing Company | Inclusion complexes providing second harmonic generation |
US5760015A (en) | 1988-01-19 | 1998-06-02 | The Trustees Of The University Of Pennsylvania | Cyclodextrin compounds and methods of making and use thereof |
JP2670680B2 (ja) | 1988-02-24 | 1997-10-29 | 株式会社ビーエムジー | 生理活性物質含有ポリ乳酸系微小球およびその製造法 |
JP2614081B2 (ja) | 1988-05-27 | 1997-05-28 | 大塚化学株式会社 | 光学活性β−ラクタム誘導体の製造法 |
US4887778A (en) | 1988-06-01 | 1989-12-19 | Universal Instruments Corporation | Feeder drive assembly and replaceable section for tape supplying and cover peeling |
JPH01319502A (ja) * | 1988-06-21 | 1989-12-25 | Showa Denko Kk | シクロデキストリン誘導体及びその製造方法 |
HU200913B (en) | 1988-07-28 | 1990-09-28 | Ciklodextrin Kutato Fejlesztoe | Process for producing infusion stock-solution containing pharmaceutically active components of bad water solubility |
MY106598A (en) | 1988-08-31 | 1995-06-30 | Australian Commercial Res & Development Ltd | Compositions and methods for drug delivery and chromatography. |
US5098793A (en) | 1988-09-29 | 1992-03-24 | Uop | Cyclodextrin films on solid substrates |
US4902788A (en) | 1988-09-29 | 1990-02-20 | Uop | Crosslinked cyclodextrins supported on porous refractory inorganic oxides |
IT1230566B (it) | 1988-10-17 | 1991-10-28 | Vectorpharma Int | Farmaci poco solubili supportati su sostanze polimeriche in forma atta all'aumento della velocita' di dissoluzione |
US5688488A (en) | 1989-04-03 | 1997-11-18 | Purdue Research Foundation | Composition and method for tumor imaging |
US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
US5424186A (en) | 1989-06-07 | 1995-06-13 | Affymax Technologies N.V. | Very large scale immobilized polymer synthesis |
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
JPH03221505A (ja) | 1990-01-29 | 1991-09-30 | Toppan Printing Co Ltd | シクロデキストリンポリマーの合成方法及びシクロデキストリン膜の製造方法 |
EP0518930A4 (en) * | 1990-03-02 | 1993-09-15 | Australian Commercial Research & Development Limited | Cyclodextrin compositions and methods for pharmaceutical and industrial applications |
IT1241417B (it) | 1990-03-06 | 1994-01-14 | Vectorpharma Int | Composizioni terapeutiche a rilascio controllato di farmaci supportatisu polimeri reticolati e rivestiti con film polimerici,e loro processodi preparazione |
DE4009825A1 (de) | 1990-03-27 | 1991-10-02 | Consortium Elektrochem Ind | Wasserunloesliche cyclodextrin-polymerisate und verfahren zu deren herstellung |
US5139687A (en) | 1990-05-09 | 1992-08-18 | The Proctor & Gamble Company | Non-destructive carriers for cyclodextrin complexes |
JPH0425505A (ja) | 1990-05-21 | 1992-01-29 | Toppan Printing Co Ltd | シクロデキストリンポリマー及びシクロデキストリン膜の製造方法 |
US5650489A (en) | 1990-07-02 | 1997-07-22 | The Arizona Board Of Regents | Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof |
FR2665169A1 (fr) | 1990-07-30 | 1992-01-31 | Rhone Poulenc Chimie | Composes d'inclusion de cyclodextrines enfermant des antioxydants phenoliques et leur utilisation dans les polymeres. |
JPH04106101A (ja) | 1990-08-27 | 1992-04-08 | Showa Denko Kk | シクロデキストリンポリマーおよびその製造方法 |
EP0477931B1 (en) * | 1990-09-28 | 1994-08-17 | Mercian Corporation | Novel adriamycin derivatives |
JPH059205A (ja) * | 1990-09-28 | 1993-01-19 | Mercian Corp | 新規なアドリアマイシン誘導体 |
US5208316A (en) * | 1990-10-01 | 1993-05-04 | Toppan Printing Co., Ltd. | Cyclodextrin polymer and cyclodextrin membrane prepared using said polymer |
EP0513358B1 (en) | 1990-11-30 | 1997-10-01 | Toppan Printing Co., Ltd. | Process for producing cyclodextrin derivative and polymer containing cyclodextrin immobilized therein |
EP1046421B8 (en) | 1990-12-06 | 2006-01-11 | Affymetrix, Inc. (a Delaware Corporation) | Methods and reagents for very large scale immobilized polymer synthesis |
US5148854A (en) | 1990-12-11 | 1992-09-22 | Toshiba Kikai Kabushiki Kaisha | Counting die cast manufactured goods |
NO180605C (no) | 1990-12-19 | 2003-08-28 | Geco As | Anordning til vektbelastning av streamerkabel |
US5330768A (en) | 1991-07-05 | 1994-07-19 | Massachusetts Institute Of Technology | Controlled drug delivery using polymer/pluronic blends |
US5714512A (en) | 1991-07-08 | 1998-02-03 | Rhone-Poulenc Rorer, S.A. | Compositions containing taxane derivatives |
US5750561A (en) | 1991-07-08 | 1998-05-12 | Rhone-Poulenc Rorer, S.A. | Compositions containing taxane derivatives |
US5698582A (en) | 1991-07-08 | 1997-12-16 | Rhone-Poulenc Rorer S.A. | Compositions containing taxane derivatives |
CA2116431A1 (en) | 1991-09-06 | 1993-03-18 | Gurcharn S. Sidhu | Composition and method for reducing cholesterol concentration |
NZ244306A (en) | 1991-09-30 | 1995-07-26 | Boehringer Ingelheim Int | Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation |
US5837747A (en) | 1991-10-29 | 1998-11-17 | Vivorx, Inc. | Crosslinkable polysaccharides, polycations and lipids useful for encapsulation and drug release |
US6849462B1 (en) | 1991-11-22 | 2005-02-01 | Affymetrix, Inc. | Combinatorial strategies for polymer synthesis |
JP2976154B2 (ja) | 1991-11-27 | 1999-11-10 | コニカ株式会社 | ハロゲン化銀写真感光材料用固形処理剤 |
JP3221505B2 (ja) | 1992-02-06 | 2001-10-22 | 日本信号株式会社 | 移動体の運行管理装置 |
US5219980A (en) | 1992-04-16 | 1993-06-15 | Sri International | Polymers biodegradable or bioerodiable into amino acids |
JPH05331074A (ja) | 1992-05-27 | 1993-12-14 | Nippon Oil & Fats Co Ltd | 薬物運搬体 |
GB9211268D0 (en) | 1992-05-28 | 1992-07-15 | Ici Plc | Salts of basic peptides with carboxyterminated polyesters |
IT1256134B (it) | 1992-09-09 | 1995-11-29 | Luigi Boltri | Sali lipofili contenenti isotopi neutron attivabili e composizioni che li contengono |
US5482719A (en) | 1992-10-30 | 1996-01-09 | Guillet; James E. | Drug delivery systems |
DK0624166T3 (da) | 1992-11-30 | 1997-10-06 | Ciba Geigy Ag | Polymeriserbare carbohydratestere, polymerer fremstillet deraf og deres anvendelse |
FR2698543B1 (fr) | 1992-12-02 | 1994-12-30 | Rhone Poulenc Rorer Sa | Nouvelles compositions à base de taxoides. |
US6749868B1 (en) | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
BR9405798A (pt) | 1993-02-22 | 1995-12-12 | Vivorx Pharmaceuticals Inc | Métodos para liberação in vivo de material biológico e composições úteis dos mesmos |
US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
US5439686A (en) | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
US6753006B1 (en) | 1993-02-22 | 2004-06-22 | American Bioscience, Inc. | Paclitaxel-containing formulations |
US5298410A (en) * | 1993-02-25 | 1994-03-29 | Sterling Winthrop Inc. | Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life |
HU210922B (en) | 1993-05-24 | 1995-09-28 | Europharmaceuticals Sa | Nimesulide alkali salt cyclodextrin inclusion complexes their preparation and pharmaceutical compositions containing them |
US5840485A (en) | 1993-05-27 | 1998-11-24 | Selectide Corporation | Topologically segregated, encoded solid phase libraries |
TW328535B (en) | 1993-07-02 | 1998-03-21 | Novartis Ag | Functional photoinitiators and their manufacture |
JP3288149B2 (ja) | 1993-08-05 | 2002-06-04 | 日本食品化工株式会社 | シクロデキストリンポリマー及びその製造方法 |
RU2094059C1 (ru) | 1993-08-30 | 1997-10-27 | Московский государственный университет, химический факультет | Способ транспорта нейротропных препаратов в мозг |
US5616568A (en) | 1993-11-30 | 1997-04-01 | The Research Foundation Of State University Of New York | Functionalized derivatives of hyaluronic acid |
US5880154A (en) | 1994-02-01 | 1999-03-09 | The Board Of Regents Of The University Of Nebraska | Polymeric adamantane analogues |
TW307775B (en) | 1994-02-15 | 1997-06-11 | Novartis Erfind Verwalt Gmbh | Unsaturated carbohydrate derivatives, polymers thereof and their use |
DE699079T1 (de) | 1994-03-07 | 1997-09-25 | Dendritech Inc | Bioaktive und/oder gezielte dendrimere-konjugate |
JPH07316205A (ja) | 1994-03-30 | 1995-12-05 | D D S Kenkyusho:Kk | シクロデキストリン誘導体 |
HU218280B (en) | 1994-04-26 | 2000-07-28 | Cyclodextrin inclusion complexes containing sin-1a which are stable intheir solid state, process for their preparation and pharmaceutical compositions containing the comlexes | |
US6589736B1 (en) | 1994-11-22 | 2003-07-08 | The Trustees Of Boston University | Photocleavable agents and conjugates for the detection and isolation of biomolecules |
US5691316A (en) | 1994-06-01 | 1997-11-25 | Hybridon, Inc. | Cyclodextrin cellular delivery system for oligonucleotides |
US5716594A (en) | 1994-06-06 | 1998-02-10 | The Jmde Trust | Biotin compounds for targetting tumors and sites of infection |
US5776842A (en) | 1994-06-23 | 1998-07-07 | Cellresin Technologies, Llc | Cellulosic web with a contaminant barrier or trap |
US5679773A (en) | 1995-01-17 | 1997-10-21 | Affymax Technologies N.V | Reagants and methods for immobilized polymer synthesis and display |
US5739386A (en) | 1994-06-23 | 1998-04-14 | Affymax Technologies N.V. | Photolabile compounds and methods for their use |
US5549974A (en) | 1994-06-23 | 1996-08-27 | Affymax Technologies Nv | Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof |
US5494854A (en) | 1994-08-17 | 1996-02-27 | Texas Instruments Incorporated | Enhancement in throughput and planarity during CMP using a dielectric stack containing HDP-SiO2 films |
JP3699141B2 (ja) | 1994-09-24 | 2005-09-28 | 伸彦 由井 | 超分子構造の生体内分解性医薬高分子集合体及びその調製方法 |
US5548932A (en) * | 1994-11-08 | 1996-08-27 | Maxcess Technologies, Inc. | Adjustable cable tray support system |
US6353055B1 (en) | 1994-11-18 | 2002-03-05 | Supratek Pharma Inc. | Polynucleotide compositions |
US5656611A (en) | 1994-11-18 | 1997-08-12 | Supratek Pharma Inc. | Polynucleotide compositions |
MA23823A1 (fr) | 1995-03-27 | 1996-10-01 | Aventis Pharma Sa | Nouveaux taxoides, leur preparation et les compositions qui les contiennent |
US6372780B2 (en) | 1995-03-27 | 2002-04-16 | Aventis Pharma S.A. | Methods of treating cell lines expressing multidrug resistance P-glycoprotein |
US5847170A (en) | 1995-03-27 | 1998-12-08 | Rhone-Poulenc Rorer, S.A. | Taxoids, their preparation and pharmaceutical compositions containing them |
US5728804A (en) | 1995-06-02 | 1998-03-17 | Research Corporation Technologies, Inc. | Use of cyclodextrins for protein renaturation |
US6667293B1 (en) | 1995-09-12 | 2003-12-23 | Hybridon, Inc. | Use of cyclodextrins to modulate gene expression with reduced immunostimulatory response |
US6441025B2 (en) | 1996-03-12 | 2002-08-27 | Pg-Txl Company, L.P. | Water soluble paclitaxel derivatives |
PL189698B1 (pl) | 1996-03-12 | 2005-09-30 | Pg Txl Co | Kompozycja farmaceutyczna zawierająca lek przeciwnowotworowy i jej zastosowania |
JP3830198B2 (ja) | 1996-03-29 | 2006-10-04 | 東光薬品工業株式会社 | 超分子構造高分子集合体を用いた皮膚透過性インドメタシン外用剤 |
DE19612768A1 (de) | 1996-03-29 | 1997-10-02 | Basf Ag | Cyclodextringruppen enthaltende Polymere, Verfahren zu ihrer Herstellung und ihre Verwendung |
JPH11514388A (ja) * | 1996-04-03 | 1999-12-07 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | シクロデキストリン化合物ならびにその製造法および使用 |
US5844030A (en) | 1996-07-09 | 1998-12-01 | Andros; Nicholas | Charged ion cleaning devices and cleaning system |
DE19629494A1 (de) | 1996-07-09 | 1998-01-15 | Schering Ag | Pseudopolyrotaxane |
US6232434B1 (en) * | 1996-08-02 | 2001-05-15 | Duke University Medical Center | Polymers for delivering nitric oxide in vivo |
US5770645A (en) * | 1996-08-02 | 1998-06-23 | Duke University Medical Center | Polymers for delivering nitric oxide in vivo |
DE69720041T2 (de) | 1996-11-14 | 2004-01-08 | Affymetrix, Inc., Santa Clara | Chemische amplifizierung zur synthese von musterordnungen |
JPH10158195A (ja) | 1996-11-28 | 1998-06-16 | Res Inst For Prod Dev | 配位結合を利用した薬物−高分子複合体製剤の調製方法 |
US6495579B1 (en) | 1996-12-02 | 2002-12-17 | Angiotech Pharmaceuticals, Inc. | Method for treating multiple sclerosis |
HUP9700632A3 (en) | 1997-03-24 | 1999-10-28 | Cyclolab Ciklodextrin Kutato F | Pharmaceutical compositions containing propylamine derivative and cyclodextrine and process for producing the same |
WO1998047496A2 (en) * | 1997-04-18 | 1998-10-29 | Access Pharmaceuticals, Inc. | Polymer-platinum compounds |
AU743204B2 (en) | 1997-04-23 | 2002-01-24 | University Of Otago | Controlled release of ophthalmic compositions |
WO1998049350A1 (en) | 1997-04-30 | 1998-11-05 | Regents Of The University Of Minnesota | In vivo use of recombinagenic oligonucleobases to correct genetic lesions in hepatocytes |
US5990237A (en) | 1997-05-21 | 1999-11-23 | Shearwater Polymers, Inc. | Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines |
WO1998056370A2 (en) | 1997-06-13 | 1998-12-17 | Johns Hopkins University School Of Medicine | Therapeutic nanospheres |
DE19726186A1 (de) | 1997-06-20 | 1998-12-24 | Boehringer Ingelheim Int | Komplexe für den Transport von Nukleinsäure in höhere eukaryotische Zellen |
JPH11100401A (ja) | 1997-07-30 | 1999-04-13 | Kikkoman Corp | 環状オリゴ糖及びそれを含むレトロウイルス性疾患の予防または治療剤 |
US6410342B1 (en) | 1997-08-19 | 2002-06-25 | Pharmacopeia, Inc. | Method and apparatus for controlled photoelution |
EA003832B1 (ru) | 1997-09-15 | 2003-10-30 | Дженетик Иммьюнити, Ллс. | Ген-доставочный комплекс для чрескожной доставки чужеродного генетического материала в антиген-презентирующие клетки и способы его использования |
WO1999030727A1 (en) | 1997-12-17 | 1999-06-24 | Enzon, Inc. | Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents |
US6383811B2 (en) | 1997-12-30 | 2002-05-07 | Mirus Corporation | Polyampholytes for delivering polyions to a cell |
GB9801109D0 (en) | 1998-01-20 | 1998-03-18 | Pfizer | Cyclodextrin compositions |
JP4503828B2 (ja) | 1998-02-11 | 2010-07-14 | ユニバーシティー オブ ヒューストン | 光生成試薬を用いる化学反応および生化学反応のための方法および装置 |
IT1298732B1 (it) | 1998-03-13 | 2000-02-02 | Recordati Chem Pharm | Composizioni farmaceutiche orali assumibili senza liquidi,contenenti complessi di inclusione |
US6048736A (en) | 1998-04-29 | 2000-04-11 | Kosak; Kenneth M. | Cyclodextrin polymers for carrying and releasing drugs |
WO1999061062A1 (en) | 1998-05-29 | 1999-12-02 | Massachusetts Institute Of Technology | Cyclodextrin complexes |
US7091192B1 (en) | 1998-07-01 | 2006-08-15 | California Institute Of Technology | Linear cyclodextrin copolymers |
US6509323B1 (en) | 1998-07-01 | 2003-01-21 | California Institute Of Technology | Linear cyclodextrin copolymers |
US6261583B1 (en) | 1998-07-28 | 2001-07-17 | Atrix Laboratories, Inc. | Moldable solid delivery system |
US6703381B1 (en) | 1998-08-14 | 2004-03-09 | Nobex Corporation | Methods for delivery therapeutic compounds across the blood-brain barrier |
JP2003530297A (ja) | 1998-10-16 | 2003-10-14 | ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ, リプリゼンテッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ | Vipアンタゴニストを用いる併用療法 |
ATE356637T1 (de) | 1998-12-04 | 2007-04-15 | California Inst Of Techn | Supramolekulare komplexe enthaltende arzneimittel |
US7375096B1 (en) | 1998-12-04 | 2008-05-20 | California Institute Of Technology | Method of preparing a supramolecular complex containing a therapeutic agent and a multi-dimensional polymer network |
AU2713500A (en) | 1998-12-23 | 2000-07-31 | G.D. Searle & Co. | Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
US6740643B2 (en) | 1999-01-21 | 2004-05-25 | Mirus Corporation | Compositions and methods for drug delivery using amphiphile binding molecules |
FR2789685B1 (fr) * | 1999-02-15 | 2001-05-04 | Univ Lille Sciences Tech | Procede de fabrication de polymeres solubles et insolubles a base de cyclodextrine(s) et/ou de derives de cyclodextrine(s) et polymeres solubles a base de cyclodextrine(s) et/ou de derives de cyclodextrine(s) |
AUPP913999A0 (en) * | 1999-03-12 | 1999-04-01 | Biota Scientific Management Pty Ltd | Novel chemical compounds and their use |
FR2792942B1 (fr) | 1999-04-29 | 2001-06-08 | Commissariat Energie Atomique | Cyclodextrines amphiphiles, leur preparation et leur utilisation pour solubiliser des systemes organises et incorporer des molecules hydrophobes |
EP1102785B1 (en) | 1999-06-07 | 2013-02-13 | Arrowhead Research Corporation | COMPOSITIONS FOR DRUG DELIVERY USING pH SENSITIVE MOLECULES |
WO2000075162A1 (en) | 1999-06-07 | 2000-12-14 | Mirus Corporation | A compound containing a labile disulfide bond |
US6309633B1 (en) | 1999-06-19 | 2001-10-30 | Nobex Corporation | Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same |
US6420378B1 (en) | 1999-10-15 | 2002-07-16 | Supergen, Inc. | Inhibition of abnormal cell proliferation with camptothecin and combinations including the same |
EP1233671A4 (en) | 1999-11-29 | 2005-11-02 | Mirus Corp | COMPOSITIONS AND METHODS OF DISPOSING MEDICAMENTS USING AMPHIPHILIC BINDING MOLECULARS |
SK282717B6 (sk) | 2000-03-10 | 2002-11-06 | �Stav Experiment�Lnej Farmakol�Gie Sav | Spôsob prípravy ultravysokomolekulových hyalurónanov |
US20010041706A1 (en) | 2000-03-24 | 2001-11-15 | Synold Timothy W. | Blockade of taxane metabolism |
WO2001074401A2 (en) * | 2000-03-31 | 2001-10-11 | Supergen, Inc. | Camptothecin complexes |
JP2001288097A (ja) | 2000-04-07 | 2001-10-16 | Pg-Txl Co Lp | 水溶性パクリタキセル誘導体 |
AU7007001A (en) | 2000-06-22 | 2002-01-02 | Nitromed Inc | Nitrosated and nitrosylated taxanes, compositions and methods of use |
US6664228B1 (en) | 2000-08-10 | 2003-12-16 | Ceramoptec Industries, Inc. | Photoselective marking of biological targets |
CA2417087A1 (en) | 2000-08-01 | 2002-02-07 | Oregon Health And Science University | Mammalian dna binding membrane-associated protein-encoding gene and uses |
TWI321054B (en) * | 2000-12-19 | 2010-03-01 | California Inst Of Techn | Compositions containing inclusion complexes |
JP2004521109A (ja) | 2001-01-17 | 2004-07-15 | ザイコス インク. | 核酸輸送用製剤 |
EP1243276A1 (en) | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
US6828392B2 (en) | 2001-08-28 | 2004-12-07 | Carlsberg A/S | Hydroxy and amine functionalized resins |
US20030129262A1 (en) | 2001-08-30 | 2003-07-10 | Epner Daniel E. | Methionine restriction for cancer therapy |
US20030049203A1 (en) | 2001-08-31 | 2003-03-13 | Elmaleh David R. | Targeted nucleic acid constructs and uses related thereto |
US20040063654A1 (en) | 2001-11-02 | 2004-04-01 | Davis Mark E. | Methods and compositions for therapeutic use of RNA interference |
IL161733A0 (en) | 2001-11-02 | 2005-11-20 | Insert Therapeutics Inc | Methods and compositions for therapeutic use of rna interference |
US20030134824A1 (en) | 2001-11-12 | 2003-07-17 | Ronald Breslow | Beta-cyclodextrin dimers and phthalocyanines and uses thereof |
US7141540B2 (en) * | 2001-11-30 | 2006-11-28 | Genta Salus Llc | Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof |
US6527887B1 (en) | 2002-01-18 | 2003-03-04 | Mach I, Inc. | Polymeric cyclodextrin nitrate esters |
CN1305932C (zh) | 2002-02-22 | 2007-03-21 | 植入疗法公司 | 碳水化合物修饰的聚合物、其组合物及其应用 |
EP2266590A3 (en) * | 2002-02-22 | 2011-04-20 | Shire LLC | Active agent delivery sytems and methods for protecting and administering active agents |
AU2003243561A1 (en) | 2002-06-14 | 2003-12-31 | Bristol-Myers Squibb Company | Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
AU2003253048A1 (en) | 2002-07-09 | 2004-01-23 | Morphochem Aktiengellschaft Fur Kombinatorische Chemie | Tubulysin conjugates |
CA2490007C (en) | 2002-07-19 | 2011-05-24 | Omeros Corporation | Biodegradable triblock copolymers, synthesis methods therefor, and hydrogels and biomaterials made there from |
WO2004017904A2 (en) | 2002-08-23 | 2004-03-04 | The Mclean Hospital Corporation | Corticosteroid conjugates and uses thereof |
US20050271615A1 (en) | 2002-08-30 | 2005-12-08 | Doron Shabat | Self-immolative dendrimers releasing many active moieties upon a single activating event |
US20040047835A1 (en) | 2002-09-06 | 2004-03-11 | Cell Therapeutics, Inc. | Combinatorial drug therapy using polymer drug conjugates |
MX367615B (es) | 2002-09-06 | 2019-08-28 | Cerulean Pharma Inc | Polimeros a base de ciclodextrina para el suministro de agentes terapeuticos. |
CA2818071C (en) | 2002-09-06 | 2015-08-18 | Cerulean Pharma Inc. | Modified cyclodextrin ring compounds having exactly two hydroxyl moieties substituted with an amino acid for therapeutics delivery |
EP1549269A4 (en) * | 2002-10-09 | 2010-10-06 | Cerulean Pharma Inc | CYCLODEXTRIN BASED MATERIALS, COMPOSITIONS AND ITS USE |
JP2006504743A (ja) | 2002-10-09 | 2006-02-09 | コーザン バイオサイエンシス インコーポレイテッド | 治療製剤 |
US7495099B2 (en) | 2002-10-31 | 2009-02-24 | Nippon Kayaku Kabushiki Kaisha | High-molecular weight derivatives of camptothecins |
EP1560931B1 (en) | 2002-11-14 | 2011-07-27 | Dharmacon, Inc. | Functional and hyperfunctional sirna |
US7550470B2 (en) | 2002-12-11 | 2009-06-23 | Merck & Co. Inc. | Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors |
EP2529758A3 (en) | 2003-01-27 | 2013-01-02 | Endocyte, Inc. | Vitamin receptor binding drug delivery conjugates |
US7358262B2 (en) | 2003-01-29 | 2008-04-15 | Whitehead Institute For Biomedical Research | Identification of genotype-selective anti-tumor agents |
CN1216057C (zh) | 2003-03-28 | 2005-08-24 | 贵州省生物研究所 | 喜树碱类似物的衍生物及其制备方法 |
CA2526085A1 (en) | 2003-05-30 | 2005-01-06 | Genentech, Inc. | Treatment with anti-vegf antibodies |
EP1525890A1 (en) | 2003-10-02 | 2005-04-27 | Complex Biosystems GmbH | Protein-Proteophore complexes |
WO2006004574A2 (en) | 2004-02-19 | 2006-01-12 | Abbott Laboratories | Method for using gamma cyclodextrin to control blood glucose and insulin secretion |
WO2005118876A2 (en) | 2004-06-04 | 2005-12-15 | Genentech, Inc. | Egfr mutations |
WO2006012527A1 (en) | 2004-07-23 | 2006-02-02 | Endocyte, Inc. | Bivalent linkers and conjugates thereof |
US8975248B2 (en) | 2004-12-15 | 2015-03-10 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Combinations of therapeutic agents for treating cancer |
TW200640493A (en) | 2005-02-16 | 2006-12-01 | Insert Therapeutics Inc | Cyclodextrin-based polymers for therapeutics delivery |
PL3248600T3 (pl) | 2005-02-18 | 2020-09-07 | Abraxis Bioscience, Llc | Połączenia i sposoby podawania środków terapeutycznych i terapia skojarzona |
BRPI0608173A2 (pt) | 2005-02-24 | 2010-11-09 | Elan Pharma Int Ltd | composição, uso da mesma, e, método de produzir uma composição de docetaxel nanoparticulada ou análogo do mesmo |
JP2008537551A (ja) | 2005-03-31 | 2008-09-18 | カランド ファーマシューティカルズ, インコーポレイテッド | リボヌクレオチドレダクターゼサブユニット2の阻害剤およびその使用 |
PL1913157T5 (pl) | 2005-06-28 | 2017-09-29 | Genentech Inc | Mutacje EGFR i KRAS do prognozowania reakcji pacjenta na leczenie inhibitorem EGFR |
JP4994618B2 (ja) | 2005-08-11 | 2012-08-08 | 学校法人北里研究所 | Ts−1/カンプトテシン類による化学放射線療法 |
US8143236B2 (en) | 2005-12-13 | 2012-03-27 | Bionumerik Pharmaceuticals, Inc. | Chemoprotective methods |
US7897568B2 (en) | 2006-03-03 | 2011-03-01 | Vinay K. Singh | Compositions for treatment of cancer |
KR100917809B1 (ko) | 2006-05-22 | 2009-09-18 | 에스케이케미칼주식회사 | 우수한 저장안정성을 갖는 도세탁셀 함유 주사제 조성물 |
US20100112077A1 (en) | 2006-11-06 | 2010-05-06 | Abraxis Bioscience, Llc | Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer |
TWI528976B (zh) | 2006-12-13 | 2016-04-11 | 斯茹林製藥公司 | 用於醫物傳遞之以環糊精為基之聚合物 |
JP2010516625A (ja) | 2007-01-24 | 2010-05-20 | インサート セラピューティクス, インコーポレイテッド | 制御された薬物送達のためのテザー基を有するポリマー−薬物コンジュゲート |
US20110177161A1 (en) | 2007-05-24 | 2011-07-21 | Dr. Reddy's Laboratories Limited | Pharmaceutical compositions of [5(s)-(2'-hydroxyethoxy)-20(s)-camptothecin |
FR2918279B1 (fr) | 2007-07-05 | 2010-10-22 | Aventis Pharma Sa | Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan |
AU2008338526A1 (en) | 2007-12-14 | 2009-06-25 | Immune Disease Institute, Inc. | Treatment and prevention of HIV infection |
WO2009123764A2 (en) | 2008-04-04 | 2009-10-08 | Calando Pharmaceuticals, Inc. | Compositions and use of epas1 inhibitors |
WO2010025337A1 (en) | 2008-08-29 | 2010-03-04 | Enzon Pharmaceuticals, Inc. | Method of treating ras associated cancer |
EP2344161B1 (en) | 2008-10-16 | 2018-12-19 | Celator Pharmaceuticals, Inc. | Combinations of a liposomal water-soluble camptothecin with cetuximab or bevacizumab |
CA2756072A1 (en) | 2009-03-30 | 2010-10-14 | Cerulean Pharma Inc. | Polymer-agent conjugates, particles, compositions, and related methods of use |
US20110245201A1 (en) | 2009-09-15 | 2011-10-06 | John Ryan | Treatment of cancer |
EA201200486A1 (ru) | 2009-09-15 | 2012-08-30 | Серулин Фарма Инк. | Лечение онкологических заболеваний |
US20120114658A1 (en) | 2009-09-15 | 2012-05-10 | John Ryan | Treatment of cancer |
US20130029909A1 (en) | 2009-09-15 | 2013-01-31 | John Ryan | Treatment of cancer |
CN102781237A (zh) | 2009-11-23 | 2012-11-14 | 天蓝制药公司 | 用于传递治疗剂的基于环糊精的聚合物 |
US20110178287A1 (en) | 2010-01-19 | 2011-07-21 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutic delivery |
US9062094B2 (en) | 2010-01-22 | 2015-06-23 | Ascendis Pharma As | Dipeptide-based prodrug linkers for aliphatic amine-containing drugs |
WO2011119262A1 (en) | 2010-03-26 | 2011-09-29 | Cerulean Pharma Inc. | Methods and systems for generating nanoparticles |
CA2799202C (en) | 2010-05-18 | 2016-07-05 | Cerulean Pharma Inc. | Compositions and methods for treatment of autoimmune and other diseases |
WO2012044832A1 (en) | 2010-09-30 | 2012-04-05 | Fetzer Oliver S | Methods of treating a subject and related particles, polymers and compositions |
EP2463289A1 (en) | 2010-11-26 | 2012-06-13 | Almirall, S.A. | Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors |
EP2756309B1 (en) | 2011-09-12 | 2015-07-22 | Universiteit Gent | Neuregulin-1-based prognosis and therapeutic stratification of colorectal cancer |
US9200035B2 (en) | 2011-10-21 | 2015-12-01 | University of Pittsburgh—of the Commonwealth System of Higher Education | Bifunctional compounds |
US20140105891A1 (en) | 2012-10-05 | 2014-04-17 | Cerulean Pharma Inc. | Treatment of cancer |
-
2003
- 2003-09-04 MX MX2013004590A patent/MX367615B/es unknown
- 2003-09-04 PT PT03770286T patent/PT1534340E/pt unknown
- 2003-09-04 EP EP10184901.6A patent/EP2402036B1/en not_active Expired - Lifetime
- 2003-09-04 BR BR122012021252A patent/BR122012021252B8/pt active IP Right Grant
- 2003-09-04 JP JP2004569982A patent/JP2006502301A/ja not_active Withdrawn
- 2003-09-04 ES ES10184884T patent/ES2417324T3/es not_active Expired - Lifetime
- 2003-09-04 AT AT03770286T patent/ATE533513T1/de active
- 2003-09-04 KR KR1020147014132A patent/KR20140070676A/ko active Search and Examination
- 2003-09-04 WO PCT/US2003/027588 patent/WO2004022099A2/en active Application Filing
- 2003-09-04 ES ES10184901.6T patent/ES2666694T3/es not_active Expired - Lifetime
- 2003-09-04 CA CA2497792A patent/CA2497792C/en not_active Expired - Lifetime
- 2003-09-04 MX MXPA05002444A patent/MXPA05002444A/es active IP Right Grant
- 2003-09-04 EP EP17209803.0A patent/EP3332811A1/en active Pending
- 2003-09-04 ES ES03770286T patent/ES2377318T3/es not_active Expired - Lifetime
- 2003-09-04 CN CN201110329366.XA patent/CN102516417B/zh not_active Expired - Lifetime
- 2003-09-04 BR BRPI0314042A patent/BRPI0314042B8/pt not_active IP Right Cessation
- 2003-09-04 KR KR1020127020305A patent/KR20120104412A/ko not_active IP Right Cessation
- 2003-09-04 AU AU2003278764A patent/AU2003278764C1/en not_active Expired
- 2003-09-04 EP EP03770286A patent/EP1534340B1/en not_active Expired - Lifetime
- 2003-09-04 PT PT101848844T patent/PT2277551E/pt unknown
- 2003-09-04 CN CN201410658743.8A patent/CN104383554B/zh not_active Expired - Lifetime
- 2003-09-04 KR KR1020137006800A patent/KR101476067B1/ko active IP Right Grant
- 2003-09-04 KR KR1020057003918A patent/KR101268258B1/ko active IP Right Review Request
- 2003-09-04 KR KR1020177037716A patent/KR102008768B1/ko active IP Right Grant
- 2003-09-04 EP EP10184884.4A patent/EP2277551B1/en not_active Expired - Lifetime
- 2003-09-04 KR KR1020167024300A patent/KR101857900B1/ko active IP Right Grant
- 2003-09-05 TW TW100146937A patent/TWI422379B/zh not_active IP Right Cessation
- 2003-09-05 TW TW092124615A patent/TWI366464B/zh not_active IP Right Cessation
- 2003-09-05 US US10/656,838 patent/US7270808B2/en active Active
-
2005
- 2005-06-15 HK HK05104980.9A patent/HK1072202A1/xx not_active IP Right Cessation
- 2005-06-15 HK HK11105534.9A patent/HK1151467A1/xx not_active IP Right Cessation
-
2007
- 2007-07-25 US US11/881,325 patent/US8110179B2/en active Active
-
2009
- 2009-12-24 AU AU2009251190A patent/AU2009251190C1/en not_active Expired
-
2011
- 2011-01-06 JP JP2011001566A patent/JP5586487B2/ja not_active Expired - Lifetime
- 2011-10-20 US US13/277,780 patent/US8314230B2/en not_active Expired - Lifetime
-
2012
- 2012-01-12 JP JP2012004159A patent/JP5681646B2/ja not_active Expired - Lifetime
- 2012-02-16 CY CY20121100157T patent/CY1112362T1/el unknown
- 2012-03-15 US US13/421,839 patent/US8252276B2/en not_active Expired - Lifetime
- 2012-07-19 US US13/553,376 patent/US8399431B2/en not_active Expired - Lifetime
- 2012-07-19 US US13/553,400 patent/US8389499B2/en not_active Expired - Lifetime
- 2012-08-10 US US13/572,283 patent/US8404662B2/en not_active Expired - Lifetime
- 2012-08-10 US US13/572,294 patent/US8680202B2/en not_active Expired - Lifetime
- 2012-08-10 US US13/572,243 patent/US8475781B2/en not_active Expired - Lifetime
-
2013
- 2013-01-11 US US13/739,864 patent/US8518388B2/en not_active Expired - Lifetime
- 2013-01-11 US US13/739,896 patent/US8609081B2/en not_active Expired - Lifetime
- 2013-01-11 US US13/739,881 patent/US8580242B2/en not_active Expired - Lifetime
- 2013-02-15 US US13/769,052 patent/US8580244B2/en not_active Expired - Lifetime
- 2013-02-15 US US13/769,076 patent/US8603454B2/en not_active Expired - Lifetime
- 2013-02-15 US US13/769,019 patent/US8580243B2/en not_active Expired - Lifetime
- 2013-07-31 CY CY20131100656T patent/CY1114941T1/el unknown
- 2013-10-17 US US14/056,554 patent/US20140044669A1/en not_active Abandoned
- 2013-10-24 US US14/061,868 patent/US9550860B2/en not_active Expired - Lifetime
-
2014
- 2014-05-27 JP JP2014108845A patent/JP5934743B2/ja not_active Expired - Lifetime
- 2014-07-21 US US14/336,495 patent/US20150165055A1/en not_active Abandoned
- 2014-09-18 IL IL234716A patent/IL234716A0/he unknown
- 2014-09-18 IL IL234715A patent/IL234715A0/he unknown
-
2017
- 2017-03-07 US US15/451,861 patent/US20170369651A1/en not_active Abandoned
-
2018
- 2018-10-23 HK HK18113565.8A patent/HK1254600A1/zh unknown
-
2021
- 2021-01-08 US US17/144,598 patent/US20210128516A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1254600A1 (zh) | 用於輸送與其共價結合喜樹鹼的基於環糊精的聚合物 | |
TW200640493A (en) | Cyclodextrin-based polymers for therapeutics delivery | |
WO2008076333A3 (en) | Polymer-drug conjugates with tether groups for controlled drug delivery | |
Ossipov | Bisphosphonate-modified biomaterials for drug delivery and bone tissue engineering | |
Singer et al. | Water-soluble poly-(l-glutamic acid)–Gly-camptothecin conjugates enhance camptothecin stability and efficacy in vivo | |
EP2548582B1 (en) | Antitumoral bioconjugates of hyaluronic acid or its derivatives obtained by indirect chemical conjugation | |
WO2006060533A3 (en) | Conjugates of 1, 8-bis-naphthalimides with an antibody | |
ATE342054T1 (de) | Verfahren und zusammansetzung zur behandlung von krebs | |
WO2007004067A3 (en) | Methods and compositions for the delivery of biologically active agents | |
CA2387058A1 (en) | Injection vehicle for polymer-based formulations | |
ME00969B (me) | Citotoksična sredstva koja uključuju nove derivate tomajmicina i njihova upotreba u terapiji | |
WO2009095479A3 (en) | Prodrug comprising a self-cleavable linker | |
Baraldi et al. | Hybrid molecules between distamycin A and active moieties of antitumor agents | |
HK1082753A1 (en) | Taxanes covalently bound to hyaluronic acid or hyaluronic acid derivatives | |
UA103758C2 (ru) | Конъюгаты олигомеров инсулина, их композиции и применение | |
IL188774A0 (en) | Compositions for delivery of drug combinations | |
MXPA01008699A (es) | Derivados de taxano para terapia de cancer dirigida. . | |
WO2007064345A3 (en) | Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use | |
WO2005028516A3 (en) | Albumin-binding derivatives of therapeutic peptides | |
WO2004093795A3 (en) | Compositions for delivery of drug combinations | |
WO2007019478A3 (en) | Drug delivery from implants using self-assembled monolayers - therapeutic sams | |
IL154993A0 (en) | High affinity small molecule c5a receptor modulators | |
TW200612993A (en) | Lipopolymer conjugates | |
WO2001008708A3 (en) | Enhanced delivery via serpin enzyme complex receptor ligands | |
WO2004091542A3 (en) | Nitrogen containing integrin targeting compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PE | Patent expired |
Effective date: 20230901 |